Zimmer Biomet (ZBH) has dropped 22% over the past year, significantly outperforming the industry's 20.5% decline and the S&P 500's 18.3% growth. The company holds a Zacks Rank #3 (Hold) with a market capitalization of $17.18 billion. Notably, its earnings yield stands at 9.6%, which...
Analysts have provided recent insights on healthcare companies Zimmer Biomet Holdings (ZBH) and 20/20 Biolabs, Inc. (AIDX), maintaining bullish sentiments toward both stocks. TD Cowen analyst Mathew Blackman reiterated a Buy rating on Zimmer Biomet Holdings with a price target of $109.00, compared to the...
Zimmer Biomet Holdings (ZBH) announced that its prospective multicenter longitudinal cohort study titled "A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform" is complete and data have been analyzed. The trial evaluated whether Zimmer Biomet's mymobility app used with an Apple Watch could match...
At the American Academy of Orthopaedic Surgeons conference, Zimmer Biomet presented new data indicating that its Persona IQ smart knee implant yields superior patient outcomes compared to traditional implants. The analysis, derived from insurance claims and conducted by researchers at the Hospital for Special Surgery...
The Portnoy Law Firm has announced an investigation into possible securities fraud regarding Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and may file a class action lawsuit on behalf of investors. The firm is soliciting claims from shareholders who suffered losses following a significant stock price...
